All News
Ab0675 #ACR22 DAH in APLS
61 pts w APS, incident DAH
85% h/o VTE, 51% thrombocyt 43% valvulopathy
74% were on a/c at time of DAH
Relapse rate: 41% at 1 yr, 26% w/in 6 mos!!!
Risks: triple pos, thrombocyt, IVIG, PLEX, ventilation
Mortality 19% 1 yr, 38% 5 yrs
@RheumNow #ACRBest https://t.co/g1uz2Giilc
Eric Dein ericdeinmd ( View Tweet)
Among ANCA-vasculitis hospitalizations, A Fib found to be most common CV condition. Females had fewer CV complications, lower in-hospital mortality & shorter length of stay compared to males. Abs 0434 #ACR22 https://t.co/2IikApUdvE https://t.co/16ggVScs3a
Dr. Rachel Tate uptoTate ( View Tweet)
Very cool initiative @Robsonjo4
1. I love patient reported outcomes (PROs)
2. I think we under-appreciate how much steroids affect our patients quality of life
Looking forward to seeing this live!
#ACR22 #Vasculitis22 @RheumNow https://t.co/1akO1k7VgU
Mike Putman EBRheum ( View Tweet)
Interesting study about causes of death in GCA
I never know what to make of these; our pts typically die of the usual things (cancer, CVD) and have increased risks of infection (due to treatment)
Is there USA data about this?
#ACRAmbassador #ACR22 https://t.co/ZMOSD7lYGL
Mike Putman EBRheum ( View Tweet)
Abs 0478 at #ACR22 study indicates that a single screening US of temporal and axillary arteries accurately identified 83.3% of patients with subclinical GCA in an inception PMR cohort. It may not change tx but possibly timeline for tx, IMO. @RheumNow https://t.co/bEBVfxDNir https://t.co/UQ1EdniGk5
Dr. Rachel Tate uptoTate ( View Tweet)
In GCA, do you give pulse IV methylpred to patients with visual symptoms (instead of ongoing oral pred)? #ACR22 @RheumNow
David Liew drdavidliew ( View Tweet)
Terrier @TerrierBen . Pooled analysis of MAINRITSAN trials. For major relapse at 84 months RTX>AZA HR 2.5. RTX fixed-dose>tailored HR 3. RTX 18 vs 36 months equal HR 1.2 (although 78% vs 70% relapse free). @RheumNow #ACR22 Abstr#0527 https://t.co/IWQmcGeRiW
Richard Conway RichardPAConway ( View Tweet)
Jayne et al. ADVOCATE avacopan trial sub-analysis looking at patients eGFR<=20. Significantly better reduction albuminuria and increase eGFR. Numerically better recovery, lower GC, less infection @RheumNow #ACR22 Abstr#0525 https://t.co/v4ffiqfsyt https://t.co/9pK0Pn6IOj
Richard Conway RichardPAConway ( View Tweet)
Germano et al. Physical exam of temporal arteries predictive of TAB+. Decreased pulse nad thickened artery most useful @rheumnow #ACR22 Abstr#0483 https://t.co/NGvu8pMiaj https://t.co/F0Y9oy0hWy
Richard Conway RichardPAConway ( View Tweet)
Patel @NaomiRheumMD et al. Baseline GTI in GCA in GiACTA. Blood pressure and glucose tolerance biggest contributors. Higher in relapsing 122.5 vs 98.9. BMI and neuropsych higher in relapsing. @rheumnow #ACR22 Abstr#0460 https://t.co/dSIt1xEOva https://t.co/2tAkgVEEeA
Richard Conway RichardPAConway ( View Tweet)
Patel @NaomiRheumMD et al. HbA1c in GiACTA. Tocilizumab assoc HbA1c reduction independent of steroids. Daily steroid dose assoc HbA1c @rheumnow #ACR22 Abstr#0461 https://t.co/9Nbewrpww8 https://t.co/NyeTyWICF6
Richard Conway RichardPAConway ( View Tweet)
Dr. John Stone pronounces GiACTA “GEE-ACTA”. I have been pronouncing it “GIA-ACTA” and will now correct myself #vasculitis #ACR22
Catherine Sims, MD DrCassySims ( View Tweet)
Michailidou et al. Predictive models VTE in GCA. Predictors Age, inpatient status at the time of diagnosis of GCA, numberof admissions before diagnosis of GCA, Charlson comorbidity index @rheumnow #ACR22 Abstr#0458 https://t.co/TVZ53sERrS https://t.co/JzUuEZThY0
Richard Conway RichardPAConway ( View Tweet)
Henningson et al. IV methylpred in GCA. No better visual acuity, higher cumulative GC at 3 months, higher diabetes. Interesting! I find it so hard not to give, in case the contralateral eye gets it, but no evidence for this @rheumnow #ACR22 Abstr#0459 https://t.co/yMcw2HGQUx https://t.co/tNKUgYNTdG
Richard Conway RichardPAConway ( View Tweet)
We've never been convinced on adjunct therapy in GCA - yet we're still worried about aortic dilatation.
Beta-blockers we're def not doing - but impressive retrospective data here.
Let's test this properly!
ABST0477 #ACR22 @RheumNow
(also @seminarthrheum https://t.co/onKW2JKIzo) https://t.co/yHTx29NJNX
David Liew drdavidliew ( View Tweet)
Culerrier @AKronbichler @TerrierBen et al. AAV induced by anti-thyroid drugs. 45 cases. vs AAV - younger (45 vs 68) More skin (54 vs 25%) Less renal (38 vs 73%) Less severe (BVAS 9 vs 13) Less relapse (HR 0.07). Can rechallenge! @rheumnow #ACR22 Abstr#0436 https://t.co/0i7zj615N6 https://t.co/t7fWCOuUsJ
Richard Conway RichardPAConway ( View Tweet)
Froehlich et al. MRI superior to US in GCA. For all GCA sensitivity 73% vs 45%. For supra-aortic GCA sensitivity 73% vs 59%. Both 100% specificity. @rheumnow #ACR22 Abstr#0493 https://t.co/vf2r0h5zUd https://t.co/mlSCcpy2uK
Richard Conway RichardPAConway ( View Tweet)
@MayoClinic data for bari in relapsing GCA caused waves at #ACR21
Spanish data looking at real-world practice: slightly longer, slower GCA, but equally encouraging outcomes
waiting for SELECT-GCA with interest! @EBRheum
ABST0464 #ACR22 @RheumNow https://t.co/pVRPXAohhc https://t.co/FgNNfPSWk3
David Liew drdavidliew ( View Tweet)
Study of IV tocilizumab for GCA that led to FDA approval of intravenous TCZ this year (2/2022) -one of Dr. C Langford's pick for #YearinReview
@rheumnow #ACR22 https://t.co/luxDDluddM
TheDaoIndex KDAO2011 ( View Tweet)
TCZ in GCA: what does it mean for diabetes?
post-hoc GiACTA:
HbA1c obvs better with TCZ (PNL dosing)
but then: even after adjusting for PNL dose, apparent benefit
Is there protective effect?
Interesting observation worth investigating
ABST0461 @MGHrheumatology #ACR22 @RheumNow https://t.co/CF1as5y7Yy
David Liew drdavidliew ( View Tweet)
